#United States #New York #Class Action #Pomerantz Law #Altimmune

Investor Alert: Class Action Against Altimmune, Inc.

On October 3, 2025, Pomerantz LLP officially announced a class action lawsuit filed against Altimmune, Inc., which trades on the NASDAQ under the ticker ALT. This legal action arises from alleged securities fraud and other unlawful business practices involving the company and certain of its executives. Investors with losses in Altimmune are urged to consider joining the lawsuit and to contact Pomerantz for further information.

Understanding the Lawsuit

The class action specifically pertains to damages incurred by those who purchased or acquired Altimmune's securities during the designated Class Period. Legal experts remind potential participants that the deadline to request appointment as a Lead Plaintiff is fast approaching, with October 6, 2025, as the cut-off date. Interested investors should reach out to Danielle Peyton at Pomerantz LLP via email or phone, providing essential personal information, which may include their mailing address, contact number, and the number of shares they own.

Background of the Situation

The controversy surrounding Altimmune intensified after the company released its topline results from the IMPACT Phase 2b MASH trial of Pemvidutide on June 26, 2025. Initially, expectations were inflated due to previous communications from the company. However, the trial results were disappointing, showing no statistical significance in the primary endpoint concerning fibrosis reduction. This alarming news led to a drastic decline in stock value, plummeting by $4.10 per share, or nearly 53%, closing at $3.61 on the day of the announcement, highlighting a significant financial loss for many investors.

When confronted with the disappointing outcome, the company's response lacked the urgency many investors anticipated. Instead, they downplayed the results, attributing them to the Phase 2 nature of the trial and expressed hopes for improved outcomes in the subsequent Phase 3 trial. This nonchalant stance raised further concerns among shareholders about the company's commitment to transparency and due diligence in informing investors of the risks involved.

Role of Pomerantz LLP

Founded by the prominent legal figure Abraham L. Pomerantz, the firm holds an esteemed reputation in the realm of corporate, securities, and antitrust class litigation. For over 85 years, Pomerantz has championed the rights of investors affected by securities fraud and corporate misconduct. Their track record includes recovering substantial damages for numerous class members. As this case unfolds, many eyes will be on the legal efforts spearheaded by Pomerantz LLP to hold Altimmune accountable for its alleged practices.

How to Get Involved

If you are an investor who has suffered losses from your involvement with Altimmune during the specific time frame, it may be wise to act promptly. Potential participants in the class action are encouraged to contact Pomerantz LLP to discuss their individual cases and learn how they might join the legal proceedings. Further details about the lawsuit, including obtaining a copy of the Complaint, can be found on Pomerantz's official website.

In this increasingly complex business climate, investors must stay informed about potential risks associated with their investments. Engaging in class actions like this one can provide a pathway for redress and contribute to safeguarding against malpractices in the corporate world.

Conclusion

Investors who feel wronged by their experience with Altimmune have the opportunity to take collective action through this lawsuit. Pomerantz LLP is committed to fighting for the rights of affected investors, ensuring they have a voice in the judicial process. Keeping abreast of the latest developments in this case could prove crucial for those seeking compensation for their losses.